Periostat Related Published Studies
Well-designed clinical trials related to Periostat (Doxycycline Hyclate)
Administration of doxycycline in drinking water for treatment of spiral bacterial infection in cockatiels. [2008.02.01]
Regeneration of degree ii furcation defects with a 4% doxycycline hyclate bioabsorbable barrier. [2008.01]
A randomized-controlled trial of low-dose doxycycline for periodontitis in smokers. [2007.04]
Pharmacokinetic and bioequivalence study of meloxicam tablets in healthy male subjects. [2007]
The effect of topical doxycycline usage on gingival crevicular fluid MMP-8 levels of chronic and aggressive periodontitis patients: a pilot study. [2006.08]
A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. [2005.11]
Effect of locally delivered doxycycline hyclate on human fibroblast attachment to subgingival calculus. [2005.02]
The treatment of acne vulgaris with low dosage doxycycline. [2005]
Effect of subantimicrobial dose doxycycline as an effective adjunct to scaling and root planing. [2004.11]
Sustained release of doxycycline for the treatment of peri-implantitis: randomised controlled trial. [2004.10]
Initial antimicrobial effect of controlled-release doxycycline in subgingival sites. [2004.10]
Therapy with adjunctive doxycycline local delivery in patients with type 1 diabetes mellitus and periodontitis. [2004.08]
Comparative bioavailability study of doxycycline hyclate (equivalent to 100 mg doxycycline) capsules (doxycin vs vibramycin) for bioequivalence evaluation in healthy adult volunteers. [2004.07]
Comparison of the pharmacokinetic profiles of two locally administered doxycycline gels in crevicular fluid and saliva. [2004.04]
Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. [2003.04]
Tolerability of doxycycline monohydrate salt vs. chloroquine-proguanil in malaria chemoprophylaxis. [2002.11]
Utilisation of locally delivered doxycycline in non-surgical treatment of chronic periodontitis. A comparative multi-centre trial of 2 treatment approaches. [2001.08]
The effect of locally delivered controlled-release doxycycline or scaling and root planing on periodontal maintenance patients over 9 months. [2000.01]
Effects of smoking on local delivery of controlled-release doxycycline as compared to scaling and root planing. [1999.10]
Two multi-center studies evaluating locally delivered doxycycline hyclate, placebo control, oral hygiene, and scaling and root planing in the treatment of periodontitis. [1999.05]
Long-term sub-antimicrobial doxycycline (Periostat) as adjunctive management in adult periodontitis: effects on subgingival bacterial population dynamics. [1998.11]
The pharmacokinetic profile of a biodegradable controlled-release delivery system containing doxycycline compared to systemically delivered doxycycline in gingival crevicular fluid, saliva, and serum. [1998.10]
Doxycycline hyclate treatment of experimental canine ehrlichiosis followed by challenge inoculation with two Ehrlichia canis strains. [1998.02]
Multi-center comparative evaluation of subgingivally delivered sanguinarine and doxycycline in the treatment of periodontitis. II. Clinical results. [1997.02]
Randomized comparison of ofloxacin and doxycycline for chlamydia and ureaplasma urethritis and cervicitis. [1990]
Effect of oral antacid administration on the pharmacokinetics of intravenous doxycycline. [1989.04]
Well-designed clinical trials possibly related to Periostat (Doxycycline Hyclate)
Systemic MMP inhibition for periodontal wound repair: results of a multi-centre randomized-controlled clinical trial. [2009.02]
Combining host modulation and topical antimicrobial therapy in the management of moderate to severe periodontitis: a randomized multicenter trial. [2008.01]
Reduction in antimicrobial substantivity of MTAD after initial sodium hypochlorite irrigation. [2006.10]
Clinical experience results with clindamycin 1% benzoyl peroxide 5% gel (Duac) as monotherapy and in combination. [2005.03]
Local antimicrobial therapy after initial periodontal treatment. [2002.06]
The effect of postsurgical antibiotics and a bioabsorbable membrane on regenerative healing in Class II furcation defects. [1999.08]
Clinical evaluation of the use of calcium sulfate in regenerative periodontal surgery for the treatment of Class III furcation involvement. [1999]
Other research related to Periostat (Doxycycline Hyclate)
Comparative evaluation of subgingivally delivered 10% doxycycline hyclate and xanthan-based chlorhexidine gels in the treatment of chronic periodontitis. [2008.11.01]
The use and safety of doxycycline hyclate and other second-generation tetracyclines. [2008.09]
Pharmacokinetics after administration of an injectable experimental long-acting parenteral formulation of doxycycline hyclate in goats. [2008.08]
Pharmacokinetic study of an injectable long-acting parenteral formulation of doxycycline hyclate in calves. [2008.06]
A doxycycline hyclate rodent bait formulation for prophylaxis and treatment of tick-transmitted Borrelia burgdorferi. [2008.05]
A sustained-release formulation of doxycycline hyclate (Atridox) prevents simultaneous infection of Anaplasma phagocytophilum and Borrelia burgdorferi transmitted by tick bite. [2008.04]
Pharmacokinetics of doxycycline and tissue concentrations of an experimental long-acting parenteral formulation of doxycycline in Wistar rats. [2008]
Antibacterial activity and drug release of chitosan sponge containing doxycycline hyclate. [2008]
Intra-articular administration of doxycycline in calves. [2007.12]
Tick acquisition of Ehrlichia canis from dogs treated with doxycycline hyclate. [2007.09]
The use of doxycycline in periodontology. Histologic in vivo study on mice affected by diabetes mellitus. [2006.01]
Assessment of salivary levels of the chosen exoglycosidases in patients with aggressive periodontitis after treatment with doxycycline. [2006]
Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis. [2004.07]
Assessment of plasma concentrations of doxycycline in budgerigars fed medicated seed or water. [2003.10.01]
Subantimicrobial dose doxycycline for acne and rosacea. [2003.07]
The effects of subgingival calculus on the clinical outcomes of locally-delivered controlled-release doxycycline compared to scaling and root planing. [2002.02]
The significance of prior mechanical therapy for changes of periodontal status achieved by local delivery of a doxycyclinehyclate containing gel. [2001.12]
The role of Periostat in the management of adult periodontitis: a critical assessment. [1999.07]
Evaluation of Periostat for patient management. [1999.05]
Locally delivered doxycycline hyclate: case selection, preparation, and application. [1999]
The use of locally delivered doxycycline in the treatment of periodontitis. Clinical results. [1998.11]
Periodontal pocket treatment in beagle dogs using subgingival doxycycline from a biodegradable system. I. Initial clinical responses. [1996.11]
Histologic changes of doxycycline pleurodesis in rabbits. Effect of concentration and pH. [1994.10]
Effect of doxycycline hyclate on corneal epithelial wound healing in the rabbit alkali-burn model. Preliminary observations. [1993.09]
Pharmacokinetics and bioavailability of doxycycline hyclate after oral administration in calves. [1993.03]
Comparative pharmacokinetics of doxycycline in cats and dogs. [1990.12]
Pharmacokinetics and metabolic inertness of doxycycline in young pigs. [1990.08]
[Doxycycline: pharmacokinetics and suggested dosage in dogs and cats] [1988.11.01]
Therapeutic efficacy of doxycycline hyclate in experimental Escherichia coli infection in broilers. [1988.01]
Pharmacokinetics of doxycycline in dogs. [1988.01]
Other possibly related research studies
Prevention and treatment of leptospirosis. [2004.04]
Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. [2004.01]
Clinical applications for host modulatory therapy. [2002.11]
Using host response modifiers in the treatment of periodontal disease. [2002.11]
Periodontal therapy using local delivery of antimicrobial agents. [2002.10]
Locally delivered antimicrobials in periodontal treatment. [2002.06]
Systemic medications: clinical significance in periodontics. [2002.05]
Host modulation: conceptualization to clinical trials and integration into clinical practice. [2002.04]
The supplemental use of antibiotics in periodontal therapy. [1999]
Rationale for the use of Atridox therapy for managing periodontal patients. [1999]
Local delivery of antimicrobials: a new era in the treatment of adult periodontitis. [1999]
Local drug delivery in the treatment of periodontitis. [2001.10]
The malaria threat. [2001]
Failure of treatment with cephalexin for Lyme disease. [2000.06]
Facial palsy in a patient with leptospirosis: causal or accidental. [1999.03]
The role of local drug delivery in the management of periodontal diseases: a comprehensive review. [1998.05]
A double-blind, multiple-dose, placebo-controlled, cross-over study to compare the incidence of gastrointestinal complaints in healthy subjects given Doryx R and Vibramycin R. [1988.04]
Assessment and validation of animal models to evaluate topical effects of substances on gastrointestinal mucosa. [1988.03]
Rosacea: where are we now? [2004.05]
Combined local application of tetracycline and bisphosphonate reduces alveolar bone resorption in rats. [2003.07]
Antiprotozoals effective in vitro against the scuticociliate fish pathogen Philasterides dicentrarchi. [2002.06.03]
Solitary erythema migrans in Georgia and South Carolina. [1999.11]
Ophthalmic manifestations of Rochalimaea species. [1994.08.15]
Acne rosacea with keratitis in childhood. [1993.02]
Second-generation tetracyclines, a dermatologic overview: clinical uses and pharmacology. [1991.11]
Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients. [2006.07]
The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. [2006.02.15]
Cost considerations of malaria chemoprophylaxis including use of primaquine for primary or terminal chemoprophylaxis. [2006.09]
MMP inhibitors in cardiac diseases: an update. [2007.11]
Outbreak of canine monocytic ehrlichiosis in Saudi Arabia. [2007.12]
MMP inhibitors in cardiac diseases: an update. [2007.11]
EVA copolymer matrix for intra-oral delivery of antimicrobial and antiviral agents. [2008.02]
Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? [2007.06]
|
